Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis

2-7-2023: Chengdu, China: "12 trials with 448 patients showed that Actemra (tocilizumab) was the best treatment for moderate to severe Graves' ophthalmopathy, followed by Tepezza (teprotumumab) and then Rituxan (rituximab)...Actemra was also the safest" h

New Research: Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis: Backgrounds The effects of various treatments on Graves’… #Endocrinology #Endo